With an increasing prevalence due to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers and drug launches will contribute to market growth through 2029. However, this growth will be tempered by generic erosion of key brands. The relatively low diagnosis and drug-treatment rates for osteoporosis owing to the asymptomatic nature of the disease will also continue to constrain the market. Driven largely by their widespread generic availability and high physician familiarity, bisphosphonates continue to dominate first-line treatment, creating a significant barrier to uptake for novel therapies. Emerging therapies will need to demonstrate a significant risk-benefit balance at a competitive price to challenge the bisphosphonates in the first line. Therefore, most emerging therapies will compete for use as second- or third-line treatments. Questions Answered:
Scope: Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan. Primary research: 19 country-specific interviews with experts. Epidemiology: Prevalence of osteoporosis by country, with diagnosis and drug-treatment rates. Population segments in market forecast: Osteoporosis. Emerging therapies: Phase III: 1 drug; Phase II: 1 drug. Coverage of select preclinical and Phase I products. Key drugs: Denosumab, teriparatide, abaloparatide SC, abaloparatide TD, alendronate, romosozumab, raloxifene.